Jaguar animal health exhibiting at october 12-14 vcs annual conference for canalevia-ca1, the company's fda conditionally approved drug for chemotherapy-induced diarrhea (cid) in dogs

Canalevia®-ca1 is the first and only treatment for cid in dogs to receive any type of approval from the fda san francisco, ca / accesswire / october 10, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") under its jaguar animal health tradename for the veterinary market, today announced that it is exhibiting at the veterinary cancer society (vcs) annual conference, which takes place october 12-14, 2023 at the peppermill resort in reno, nevada, as part of ongoing promotional activities for canalevia-ca1 (crofelemer delayed-release tablets). canalevia-ca1, the company's u.s. food and drug administration (fda) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (cid) in dogs, is available from multiple leading veterinary distributors in the u.s. about chemotherapy-induced diarrhea (cid) in dogs due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score